HeartBeam Ranks Second Worldwide in 12-Lead ECG Innovation According to PatentVest Report

HeartBeam, a medical-technology company developing advanced electrocardiogram solutions, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics according to PatentVest's "Total Cardiac Intelligence" report. The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. This recognition highlights HeartBeam's growing influence in the next generation of cardiac monitoring technology.

The ranking underscores the rapid maturation of HeartBeam's proprietary synthesis-ECG system, which captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. In doing so, HeartBeam is addressing one of modern medicine's most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, with ischemia as a future goal.

HeartBeam is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility, thus redefining the future of cardiac health management.

The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information about the company's technology and approach, visit https://www.HeartBeam.com. Additional details about the recognition can be found in the full article at https://ibn.fm/3ADRP.

The implications of this recognition are significant for the healthcare industry and patients worldwide. As cardiac monitoring technology becomes more portable and accessible, it could lead to earlier detection of heart conditions, reduced hospital visits, and improved outcomes for patients in remote or underserved areas. The ranking positions HeartBeam as a serious contender in the competitive medical device market, potentially influencing investment decisions and partnerships within the healthcare technology sector.

For investors and industry observers, the latest news and updates relating to HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT. It's important to note that certain statements in the original article are forward-looking and involve risks, uncertainties, and other factors that may cause actual results to differ materially from expectations. These statements are subject to various risks beyond management's control, as detailed in the company's SEC filings. Full terms of use and disclaimers applicable to all content provided by IBN are available at http://IBN.fm/Disclaimer.